Skip to main content
SpringerLink
Log in

Gout plus cardiovascular disease is painful, but treatable

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Gout often coexists with and worsens cardiovascular disease (CVD) or CVD risk factors. Effective gout management reduces CVD deterioration, which includes lifestyle advice, gout flare management and long-term urate-lowering therapy (ULT). Flares respond to anti-inflammatory agents such as colchicine or short-term corticosteroids, with interleukin antagonists for refractory cases. In CVD, NSAIDs are not recommended. Allopurinol is the first-line ULT, with probenecid added or substituted where needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mouradjian MT, Plazak ME, Gale SE, et al. Pharmacologic management of gout in patients with cardiovascular disease and heart failure. Am J Cardiovasc Drugs. 2020;20(5):431–45.

    Article  Google Scholar 

  2. Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31–8.

    Article  Google Scholar 

  3. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.

    Article  CAS  Google Scholar 

  4. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res. 2020;72(6):744–60.

    Article  Google Scholar 

  5. Sivera F, Andrés M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328–35.

    Article  Google Scholar 

  6. Taylor TH, Mecchella JN, Larson RJ, et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med. 2012;125(11):1126-34.e7.

    Article  CAS  Google Scholar 

  7. Hill EM, Sky K, Sit M, et al. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol. 2015;21(3):120–5.

    Article  Google Scholar 

  8. Narang RK, Dalbeth N. Management of complex gout in clinical practice: update on therapeutic approaches. Best Pract Res Clin Rheumatol. 2018;32(6):813–34.

    Article  Google Scholar 

  9. Su CY, Shen LJ, Hsieh SC, et al. Comparing cardiovascular safety of febuxostat and allopurinol in the real world: a population-based cohort study. Mayo Clin Proc. 2019;94(7):1147–57.

    Article  Google Scholar 

  10. Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019;40(22):1778–86.

    Article  CAS  Google Scholar 

  11. MacDonald TM, Ford I, Nuki G, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014;4:e005354.

    Article  Google Scholar 

  12. Mackenzie IS, Ford I, Walker A, et al. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. BMJ Open. 2016;6(9):e013774.

    Article  Google Scholar 

  13. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47.

    Article  CAS  Google Scholar 

  14. Tardif J-C, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505.

    Article  CAS  Google Scholar 

  15. Sundy JS, Baraf HSB, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711–20.

    Article  CAS  Google Scholar 

  16. Hemkens LG, Ewald H, Gloy VL, et al. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev. 2016;1:CD011047.

    Google Scholar 

  17. Man CY, Cheung ITF, Cameron PA, et al. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49(5):670–7.

    Article  Google Scholar 

  18. Janssens HJEM, Janssen M, Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371(9627):1854–60.

    Article  CAS  Google Scholar 

  19. Billy CA, Lim RT, Ruospo M, et al. Corticosteroid or nonsteroidal antiinflammatory drugs for the treatment of acute gout: a systematic review of randomized controlled trials. J Rheumatol. 2018;45(1):128–36.

    Article  CAS  Google Scholar 

  20. Rainer TH, Cheng CH, Janssens HJEM, et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med. 2016;164(7):464–71.

    Article  Google Scholar 

  21. Souverein PC, Berard A, Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart Br Card Soc. 2004;90(8):859–65.

    Article  CAS  Google Scholar 

  22. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764–70.

    Article  Google Scholar 

  23. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.

    Article  CAS  Google Scholar 

  24. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.

    Article  Google Scholar 

  25. Sharma E, Pedersen B, Terkeltaub R. Patients prescribed anakinra for acute gout have baseline increased burden of hyperuricemia, tophi, and comorbidities, and ultimate all-cause mortality. Clin Med Insights Arthritis Musculoskelet Disord. 2019;12:1–5.

    Article  Google Scholar 

  26. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431–46.

    Article  CAS  Google Scholar 

  27. Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015;131(20):1763–71.

    Article  CAS  Google Scholar 

  28. Kim SC, Neogi T, Kang EH, et al. Cardiovascular risks of probenecid versus allopurinol in older patients with gout. J Am Coll Cardiol. 2018;71(9):994–1004.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Caroline Fenton & Arnold Lee

Authors
  1. Caroline Fenton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arnold Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnold Lee.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

C. Fenton, a contracted employee of Adis International Ltd/Springer Nature, and A. Lee, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fenton, C., Lee, A. Gout plus cardiovascular disease is painful, but treatable. Drugs Ther Perspect 37, 407–414 (2021). https://doi.org/10.1007/s40267-021-00854-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-021-00854-x

Search

Navigation